In the articles I write here you might have noticed that I usually always add at least some scientific references at the bottom, it’s common practice. I’m here making claims and as such the burden of proof is on me. But it’s also important to understand that nutrition science is a field that has many caveats and pitfalls. I’m going to explain why nutrition science has to be taken with at least several grains of salt.
Association does not mean causation
One of the biggest points is that association cannot proof causation. Things can be tightly associated with each other without being causal. In order to proof that A causes B, it is absolutely required to do a properly designed experiment. Not only would such an experiment be incredibly expensive, it’s also unethical to experiment on humans. As such, the only kind of studies we have are epidemiological in nature and as such cannot proof causation. Epidemiology is simply designed to generate hypothesis, nothing more.
Actually, not even smoking is causally linked to lung cancer, and yet it is generally regarded as causing lung cancer. How is that? This is mostly down to the Bradford Hill criteria. These criteria are meant to assess potential causality based on associative data. There is quite some debate about the validity of this method and it should not be used to establish causality. However, it can be a useful tool to assess the strength of the association and base further research on it.
Relative risk
Now, smoking & lung cancer does fulfill the Bradford Hill criteria. Without going into detail, one of the reasons is the effect size. While a small observed effect does not exclude the possibility of causality, a massive effect makes it more likely that there is a causal link.
Let’s talk about red meat for a minute, since red meat is associated with bowel cancer (and a bunch of other cancers). You’ve likely read something in the news like “Red meat increases risk of cancer by 28%!”. Not knowing about what “relative risk” means, this sounds scary.
If for example we assume that 3% of people who do not consume red meat develop colorectal cancer, a 28% increase is NOT 3%+28% = 31%! 28% means a hazard ratio of 1.28, so the result is 3%*1.28 = 3.84%. Your absolute risk in your entire lifetime goes up by only 0.84%.
In contrast: Smoking and lung cancer has a relative risk of 1500%-3000%, meaning that smoking increases your risk of lung cancer by 15-30 times.
That is why it’s a pretty safe bet to say smoking causes cancer, even though the research to actually proof it does not exist. For meat however, the difference over a lifetime is way too small. For the most part, anything that’s below 500% relative risk ratio is a nothing burger. But that’s exactly what we’re getting, 7% here, 16% there,… it may as well be statistical noise.
Replication crisis
For a study to be considered valid, its results must be reproducible. This is currently not the case for an estimated 70% of studies. Especially in nutrition science there is a lot of flip-flopping. Eggs are bad, they’ll kill you. Never mind, eggs are good. Never mind again, eggs are neutral at best. This leads to a bunch of conflicting evidence… which one is it now?
But one thing is certain:
If there was a definitive, irrefutable answer, this would not be such a hot topic for debate. This simply indicates that we do not have the answer at all, at least not in form of a study.
Significant results
A result in a published study is often referred to as “significant”. What is meant here is simply statistical significance, but it is often misinterpreted as being clinically significant. Statistical significance merely refers to the reliability of the results, meaning the results did not happen by chance. This is usually denoted by the P-Value being smaller than 0.05.
Apart from the fact that researchers can employ so-called “P-hacking” to force the value below 0.05 in order to get published in high quality science journals, it is a meaningless significance for an individual persons choices.
My post about legumes showcases this pretty well, check it out!
The data of nutrition science
Science in general relies on the collection of data. The method of collection can very much impact the results of the study.
Ethnicity, age & gender
Data collected only on Thai women aged 65-85 can only be applied to that demographic. It cannot be applied to a 25-year old European male. Different sex, different age, different genetics.
Study duration
Data collected cannot inform on anything that happens after the studies’ duration. If the study lasted 3 years, you cannot extrapolate it to 5 or 10 years.
Studied population/subjects
If the studied subjects are mice/rats/rabbits/monkeys, you cannot apply the results to humans. Humans are not rats (well, maybe some are).
Also, if your study was done on only a small number of people, it is possible that the results are simply due to chance.
Confounding variables
This is a big one. Good epidemiological studies try to control for these as much as they can, but it’s simply impossible. People have the freedom to do whatever they want, and all of it can influence the outcomes. People take drugs, drink alcohol, smoke, sit on the couch in front of the TV all day, take medications, have different genetics, (don’t) work out,… The list goes on and on and on pretty much indefinitely.
Further, in order to get any kind of statistical significant result, authors like to do something called adjustments. The idea is that somehow these confounders can be “calculated out” of the data. To be honest, I have no idea how exactly that works in practice, I’m not a statistician. But the point is we do not know how much impact each confounder actually had. How do you know how much smoking, alcohol and medication influenced the development of cancer? You don’t, it’s a guess at best. The best analogy I’ve heard for it is “Bake a cake, and once you’re done, you attempt to extract the eggs from it.”
Biases
There are many biases that can impact the results. Just to list a few important ones:
Publication bias: Studies with positive results are more likely to be published than studies with negative results.
Healthy user bias: For example, a study on the benefits of exercise could be skewed because people who regularly exercise are probably health conscious. They are also are less likely to smoke/drink/eat junkfood and are more likely to spend time outdoors.
Confirmation bias: Researchers may have preconceived notions about the outcome of the study and interpret the data to support their believe or disregard data that does not support it.
Worthy to note here, I am biased too of course.
Food frequency questionnaires
Often people are simply asked what they ate. Let alone the fact that most people have no idea what they ate for breakfast yesterday, how would you accurately estimate what you ate for the past year? How many cups of bananas did you eat in the past 6 months? And people supposedly also like to lie on these questionnaires.
Conflicts of interest
A lot of industries have a vested interest in funding studies that support their specific product. The classic one is Pharma Industry, but this applies to any industry out there. While this does not automatically mean the study can be discredited, but it should be taken into consideration.
It would not be the first time studies and researchers have been abused to put certain products into a positive light. I’m looking at you, sugar industry.
As such, authors must declare these so-called conflicts of interest not without good reason. Actually, I’m gonna put an example here because I think it’s hilarious how vast it is. Mind you: The study is simply a “consensus statement”, nothing more than a bunch of people who got together and said “Jup, we agree on this.” So let’s see who paid for this marvelous piece of work:
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
Conflict of interest: J.B. has received research grants from Amgen, AstraZeneca, NovoNordisk, Pfizer and Regeneron/Sanofi and honoraria for consultancy and lectures from Amgen, AstraZeneca, Eli Lilly, Merck, Novo-Nordisk, Pfizer, and Regeneron/Sanofi. E.B. has received honoraria from AstraZeneca, Amgen, Genfit, MSD, Sanofi-Regeneron, Unilever, Danone, Aegerion, Chiesi, Rottapharm, Lilly and research grants from Amgen, Danone and Aegerion. A.L.C. has received research grants to his institution from Amgen, Astra-Zeneca, Merck, Regeneron/Sanofi, and Sigma Tau, and honoraria for advisory boards, consultancy or speaker bureau from Abbot, Aegerion, Amgen, AstraZeneca, Eli Lilly, Genzyme, Merck/MSD,Mylan, Pfizer, Rottapharm and Sanofi-Regeneron. M.J.C. has received research grants from MSD, Kowa, Pfizer, and Randox and honoraria for consultancy/speaker activities from Amgen, Kowa, Merck, Sanofi, Servier, Unilever, and Regeneron. S.F. has the following disclosures for the last 12 months: Compensated consultant and advisory activities with Merck, Kowa, Sanofi, Amgen, Amarin, and Aegerion. B.A.F. has received research grants from Merck, Amgen and Esperion Therapeutics and received honoraria for lectures, consulting and/or advisory board membership from Merck, Amgen, Esperion, Ionis, and the American College of Cardiology. I.G. has received speaker fees from MSD and Pfizer relating to cardiovascular risk estimation and lipid guidelines, and consultancy/speaker fee from Amgen. H.N.G. has received research grants from Merck, Sanofi-Regeneron, and Amgen. He consults for Merck, Sanofi, Regeneron, Lilly, Kowa, Resverlogix, Boehringer Ingelheim. R.A.H. has received research grants from Aegerion, Amgen, The Medicines Company, Pfizer, and Sanofi. He consults for Amgen, Aegerion, Boston Heart Diagnostics, Gemphire, Lilly, and Sanofi. J.D.H reports honoraria/research grants from Aegerion, Alnylam, Catabasis, Lilly, Merck, Pfizer, Novartis, Regeneron, Sanofi. R.M.K is a Member, Merck Global Atherosclerosis Advisory Board. U.L. has received honoraria for lectures and/or consulting from Amgen, Medicines Company, Astra Zeneca, MSD, Berlin Chemie, Bayer, Abbott, and Sanofi. U.L. aufs has received honoraria for board membership, consultancy, and lectures from Amgen, MSD, Sanofi, and Servier. L.M. has received honoraria for consultancy and lectures from Amgen, Danone, Kowa, Merck, and Sanofi-Regeneron. S.J.N. has received research support from Amgen, AstraZeneca, Anthera, Cerenis, Novartis, Eli Lilly, Esperion, Resverlogix, Sanofi-Regeneron, InfraReDx. and LipoScience and is a consultant for Amgen, AstraZeneca, Boehringer Ingelheim, CSL Behring, Eli Lilly, Merck, Takeda, Pfizer, Roche, Sanofi-Regeneron, Kowa. and Novartis. B.G.N. reports consultancies and honoraria for lectures from AstraZeneca, Sanofi, Regeneron, Aegerion, Fresenius, B Braun, Kaneka, Amgen. C.J.P. has received research support from Roche, MSD and honoraria from MSD, Sanofi/Regeneron, Amgen and Pfizer. F.J.R. has received grants/research support from Amgen and Sanofi and has received speaker fees or honoraria for consultation from AstraZeneca, Merck, Amgen, and Sanofi. K.K.R. has received research grants from Amgen, Sanofi-Regeneron and Pfizer and honoraria for lectures, advisory boards or as a steering committee member from Aegerion, Amgen, Sanofi-Regeneron, Pfizer, AstraZeneca, Cerenis, ISIS Pharma, Medco, Resverlogix, Kowa, Novartis, Cipla, Lilly, Algorithm, Takeda, Boehringer Ingelheim, MSD. Esperion, and AbbieVie. H.S. has received research grants from AstraZeneca, MSD, Bayer Vital, sanofi-aventis, and Pfizer and honoraria for speaker fees from AstraZeneca, MSD, Genzyme, sanofi-aventis, and Synlab. He has consulted for MSD and AstraZeneca. M.R.T. has received speaker fees from Amgen, Astra Zeneca, Chiesi Pharma and Eli Lilly and speaker fees and research support from Amgen, Sanofi Aventis and Novo Nordisk. She has consulted for AstraZeneca. L.T. has received research funding and/or honoraria for advisory boards, consultancy or speaker bureau from Abbott Mylan, Actelion, Aegerion, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi-Sankyo, GlaxoSmithKline, Menarini, Merck, Novartis, Pfizer, Sanofi-Regeneron, Servier and Synageva. G.F.W. has received research support from Amgen and Sanofi-Regeneron. O.W. has received honoraria for lectures or consultancy from Sanofi, Amgen, MSD, and Astra-Zeneca. B.v.S, and J.K.S. report no disclosures.
How many Pharma Companies can you spot? Companies that coincidentally sell statins, a drug that lowers LDL/Cholesterol and has a market value of 14.9 billion dollars. Really makes you ponder.
Conclusions
Well… is there even a point doing studies at all? Maybe… Of course not all studies are bad, but the reality remains: None of them can or ever will inform about causality, simply because we cannot experiment on humans. For every study out there you can probably find a different one that “debunks” the first one, and so many studies are flawed and produce meaningless results. What even is left? Can we even find anything that would guide us in terms of nutrition? Do we even need that guidance? That’s a different topic that I will tackle in the future.
References
- https://www.ncbi.nlm.nih.gov/books/NBK13302/table/A5011/?report=objectonly
- https://pubmed.ncbi.nlm.nih.gov/34455534/
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3296911/
- https://www.news-medical.net/life-sciences/What-is-the-Replication-Crisis.aspx
- https://www.statista.com/chart/24899/meat-consumption-by-country/
- https://www.uicc.org/news/how-interpret-iarc-findings-red-and-processed-meat-cancer-risk-factors
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4504060/
- https://embassy.science/wiki/Theme:6b584d4e-2c9d-4e27-b370-5fbdb983ab46
- https://www.nytimes.com/2016/09/13/well/eat/how-the-sugar-industry-shifted-blame-to-fat.html
- https://academic.oup.com/eurheartj/article/38/32/2459/3745109
- https://www.imarcgroup.com/statin-market
Leave a Reply